vs
Side-by-side financial comparison of Organon & Co. (OGN) and TransUnion (TRU). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $1.2B, roughly 1.2× TransUnion). Organon & Co. runs the higher net margin — 10.0% vs 8.6%, a 1.4% gap on every dollar of revenue. On growth, TransUnion posted the faster year-over-year revenue change (13.0% vs -3.5%). Over the past eight quarters, TransUnion's revenue compounded faster (7.1% CAGR vs -4.7%).
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
TransUnion is an American consumer credit reporting agency. TransUnion collects and aggregates information on over one billion individual consumers in over thirty countries including "200 million files profiling nearly every credit-active consumer in the United States". Its customers include over 65,000 businesses. Based in Chicago, Illinois, TransUnion's 2014 revenue was US$1.3 billion. It is the smallest of the three largest credit agencies, along with Experian and Equifax.
OGN vs TRU — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $1.2B |
| Net Profit | $146.0M | $101.1M |
| Gross Margin | 53.6% | — |
| Operating Margin | — | 17.4% |
| Net Margin | 10.0% | 8.6% |
| Revenue YoY | -3.5% | 13.0% |
| Net Profit YoY | 67.8% | 52.5% |
| EPS (diluted) | $0.55 | $0.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.5B | $1.2B | ||
| Q3 25 | $1.6B | $1.2B | ||
| Q2 25 | $1.6B | $1.1B | ||
| Q1 25 | $1.5B | $1.1B | ||
| Q4 24 | $1.6B | $1.0B | ||
| Q3 24 | $1.6B | $1.1B | ||
| Q2 24 | $1.6B | $1.0B |
| Q1 26 | $146.0M | — | ||
| Q4 25 | $-205.0M | $101.1M | ||
| Q3 25 | $160.0M | $96.6M | ||
| Q2 25 | $145.0M | $109.6M | ||
| Q1 25 | $87.0M | $148.1M | ||
| Q4 24 | $109.0M | $66.3M | ||
| Q3 24 | $359.0M | $68.0M | ||
| Q2 24 | $195.0M | $85.0M |
| Q1 26 | 53.6% | — | ||
| Q4 25 | 49.2% | — | ||
| Q3 25 | 53.5% | — | ||
| Q2 25 | 54.8% | — | ||
| Q1 25 | 55.6% | — | ||
| Q4 24 | 56.3% | — | ||
| Q3 24 | 58.3% | — | ||
| Q2 24 | 58.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | -9.8% | 17.4% | ||
| Q3 25 | 15.2% | 17.8% | ||
| Q2 25 | 14.4% | 16.9% | ||
| Q1 25 | 6.7% | 23.2% | ||
| Q4 24 | 8.1% | 16.5% | ||
| Q3 24 | 13.1% | 14.4% | ||
| Q2 24 | 14.6% | 17.5% |
| Q1 26 | 10.0% | — | ||
| Q4 25 | -13.6% | 8.6% | ||
| Q3 25 | 10.0% | 8.3% | ||
| Q2 25 | 9.1% | 9.6% | ||
| Q1 25 | 5.8% | 13.5% | ||
| Q4 24 | 6.8% | 6.4% | ||
| Q3 24 | 22.7% | 6.3% | ||
| Q2 24 | 12.1% | 8.2% |
| Q1 26 | $0.55 | — | ||
| Q4 25 | $-0.78 | $0.52 | ||
| Q3 25 | $0.61 | $0.49 | ||
| Q2 25 | $0.56 | $0.56 | ||
| Q1 25 | $0.33 | $0.75 | ||
| Q4 24 | $0.42 | $0.33 | ||
| Q3 24 | $1.38 | $0.35 | ||
| Q2 24 | $0.75 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $856.3M |
| Total DebtLower is stronger | — | $4.9B |
| Stockholders' EquityBook value | — | $4.4B |
| Total Assets | — | $11.1B |
| Debt / EquityLower = less leverage | — | 1.11× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $574.0M | $856.3M | ||
| Q3 25 | $672.0M | $752.5M | ||
| Q2 25 | $599.0M | $690.0M | ||
| Q1 25 | $547.0M | $612.5M | ||
| Q4 24 | $675.0M | $682.0M | ||
| Q3 24 | $763.0M | $646.0M | ||
| Q2 24 | $704.0M | $545.8M |
| Q1 26 | — | — | ||
| Q4 25 | $8.6B | $4.9B | ||
| Q3 25 | $8.8B | — | ||
| Q2 25 | $8.9B | — | ||
| Q1 25 | $9.0B | — | ||
| Q4 24 | $8.9B | $5.1B | ||
| Q3 24 | $8.7B | — | ||
| Q2 24 | $8.7B | — |
| Q1 26 | — | — | ||
| Q4 25 | $752.0M | $4.4B | ||
| Q3 25 | $906.0M | $4.5B | ||
| Q2 25 | $733.0M | $4.5B | ||
| Q1 25 | $542.0M | $4.4B | ||
| Q4 24 | $472.0M | $4.2B | ||
| Q3 24 | $493.0M | $4.2B | ||
| Q2 24 | $144.0M | $4.1B |
| Q1 26 | — | — | ||
| Q4 25 | $12.9B | $11.1B | ||
| Q3 25 | $13.6B | $11.1B | ||
| Q2 25 | $13.5B | $11.1B | ||
| Q1 25 | $13.2B | $10.9B | ||
| Q4 24 | $13.1B | $11.0B | ||
| Q3 24 | $12.8B | $11.1B | ||
| Q2 24 | $12.2B | $11.0B |
| Q1 26 | — | — | ||
| Q4 25 | 11.49× | 1.11× | ||
| Q3 25 | 9.74× | — | ||
| Q2 25 | 12.14× | — | ||
| Q1 25 | 16.52× | — | ||
| Q4 24 | 18.81× | 1.20× | ||
| Q3 24 | 17.75× | — | ||
| Q2 24 | 60.11× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $319.5M |
| Free Cash FlowOCF − Capex | — | $222.8M |
| FCF MarginFCF / Revenue | — | 19.0% |
| Capex IntensityCapex / Revenue | — | 8.3% |
| Cash ConversionOCF / Net Profit | — | 3.16× |
| TTM Free Cash FlowTrailing 4 quarters | — | $661.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $141.0M | $319.5M | ||
| Q3 25 | $264.0M | $324.3M | ||
| Q2 25 | $220.0M | $291.3M | ||
| Q1 25 | $75.0M | $52.5M | ||
| Q4 24 | $390.0M | $254.0M | ||
| Q3 24 | $141.0M | $229.3M | ||
| Q2 24 | $332.0M | $295.2M |
| Q1 26 | — | — | ||
| Q4 25 | $96.0M | $222.8M | ||
| Q3 25 | $218.0M | $240.4M | ||
| Q2 25 | $181.0M | $214.3M | ||
| Q1 25 | $43.0M | $-15.9M | ||
| Q4 24 | $335.0M | $136.9M | ||
| Q3 24 | $99.0M | $161.3M | ||
| Q2 24 | $300.0M | $226.9M |
| Q1 26 | — | — | ||
| Q4 25 | 6.4% | 19.0% | ||
| Q3 25 | 13.6% | 20.6% | ||
| Q2 25 | 11.4% | 18.8% | ||
| Q1 25 | 2.8% | -1.5% | ||
| Q4 24 | 21.0% | 13.2% | ||
| Q3 24 | 6.3% | 14.9% | ||
| Q2 24 | 18.7% | 21.8% |
| Q1 26 | — | — | ||
| Q4 25 | 3.0% | 8.3% | ||
| Q3 25 | 2.9% | 7.2% | ||
| Q2 25 | 2.4% | 6.8% | ||
| Q1 25 | 2.1% | 6.2% | ||
| Q4 24 | 3.5% | 11.3% | ||
| Q3 24 | 2.7% | 6.3% | ||
| Q2 24 | 2.0% | 6.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.16× | ||
| Q3 25 | 1.65× | 3.36× | ||
| Q2 25 | 1.52× | 2.66× | ||
| Q1 25 | 0.86× | 0.35× | ||
| Q4 24 | 3.58× | 3.83× | ||
| Q3 24 | 0.39× | 3.37× | ||
| Q2 24 | 1.70× | 3.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
TRU
Segment breakdown not available.
